Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Chemoembolization Clear all
Terminated Phase 3 Interventional Results available

Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant

NCT03960008
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
Radiation · Procedure · Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Burlington, Massachusetts • Rochester, Minnesota • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 14, 2026, 4:59 AM EDT
Active, not recruiting Not applicable Interventional

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

NCT01918683
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT)
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Maywood, Illinois • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 14, 2026, 4:59 AM EDT
Terminated Phase 1 Interventional Results available

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

NCT01285102
View directory record Official record
Conditions
Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
irinotecan-eluting beads, hepatic artery embolization
Combination Product · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Sep 14, 2026, 4:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab

NCT00932438
View directory record Official record
Conditions
Colon Cancer With Metastases to the Liver
Interventions
LC beads loaded with Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, Bevacizumab
Device · Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Huntsville, Alabama • Sacramento, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 14, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Sorafenib on Portal Pressure

NCT01714609
View directory record Official record
Conditions
Clinically Significant Portal Hypertension
Interventions
Placebo, Sorafenib
Drug
Lead sponsor
Yale University
Other
Eligibility
20 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 14, 2026, 4:59 AM EDT
Recruiting Not applicable Interventional

Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

NCT04883671
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
Interventions
Standard of Care, SBRT
Other · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 14, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer

NCT02753881
View directory record Official record
Conditions
Liver Cancer
Interventions
whole liver lobe cTACE doxorubicin, superselective cTACE doxorubicin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 14, 2026, 4:59 AM EDT
Terminated Phase 2 Interventional Results available

LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma

NCT02524119
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
LEE011, Chemoembolization
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 14, 2026, 4:59 AM EDT
Completed Not applicable Interventional Results available

Instylla HES Hypervascular Tumor Pivotal Study

NCT04523350
View directory record Official record
Conditions
Hypervascular Tumors
Interventions
Instylla HES, TAE or cTACE
Device · Other
Lead sponsor
Instylla, Inc.
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 14, 2026, 4:59 AM EDT
Completed Not applicable Interventional Results available

Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

NCT00293397
View directory record Official record
Conditions
Liver Cancer
Interventions
Drug-eluting beads loaded with doxorubicin hydrochloride
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 14, 2026, 4:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

NCT02013778
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
HCQ
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 14, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

NCT04301778
View directory record Official record
Conditions
Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Durvalumab, SNDX-6352
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 14, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin

NCT02141906
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Oncozene-DEB-TACE
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Sep 14, 2026, 4:59 AM EDT
Terminated No phase listed Observational

Prospective Tumor Response Evaluation

NCT02787954
View directory record Official record
Conditions
Hepatocellular Cancer, Metastatic Liver Cancer
Interventions
TACE, Y-90, MWA, IRE
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 14, 2026, 4:59 AM EDT
Terminated No phase listed Observational

Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma

NCT01326390
View directory record Official record
Conditions
Kidney (Renal Cell) Cancer
Interventions
dTA/dBA C-arm fluoroscopy system with Dyna CT, DSA arteriogram- hepatic arteries, CO2 aortogram
Device · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 14, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

Contrast-enhanced Ultrasound Evaluation of Chemoembolization

NCT02764801
View directory record Official record
Conditions
Hepatocellular Carcinoma, Chemoembolization, Therapeutic
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound)
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 14, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)

NCT00023868
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFIRI regimen, cisplatin, doxorubicin hydrochloride, fluorouracil, irinotecan hydrochloride, leucovorin calcium, mitomycin C
Drug
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
9
States / cities
Tucson, Arizona • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 14, 2026, 4:59 AM EDT
Completed Phase 1 Interventional

Chemoembolization for Lung Tumors

NCT04200417
View directory record Official record
Conditions
Lung Metastases, Endobronchial Metastases, Pleural Metastases, Mediastinal Metastases
Interventions
Chemoembolization, Mitomycin C, Lipiodol, Embospheres
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 14, 2026, 4:59 AM EDT
Completed Phase 2Phase 3 Interventional

Nonpharmacologic Analgesia for Invasive Procedures

NCT00010855
View directory record Official record
Conditions
Pain, Anxiety
Interventions
Self-hypnotic relaxation
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Sep 14, 2026, 4:59 AM EDT
Withdrawn Not applicable Interventional

A Percutaneous Ultrasound Device With Needle Guide for Vascular Access

NCT03879161
View directory record Official record
Conditions
Vascular Access
Interventions
Vu-Path™
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 14, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

NCT00006016
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Interventions
thalidomide, doxorubicin hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 14, 2026, 4:59 AM EDT
Recruiting Phase 4 Interventional

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

NCT05185505
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Sep 14, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant

NCT02182687
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
Radiation · Procedure · Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 14, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

NCT04777851
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Regorafenib in combination with pembrolizumab, Loco-regional therapy
Drug · Procedure
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 14, 2026, 4:59 AM EDT